Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms ...Middle East

The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic....

Hence then, the article about antengene to present four preclinical abstracts at aacr 2024 highlighting focus on cancer immunology targeted agents and novel technology platforms was published today ( Wednesday 06/03/2024 - 03:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms )

Also on site :

• Country Icon Carrie Underwood’s Latest Career Announcement May Leave Fans Disappointed
• EU must stop funding Kiev after Zelensky’s ‘insults’ – Italian MP
• Leonardo DiCaprio Reacts to Co-Star's Oscar Nomination Snub